Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch® patient registry

Radiation Oncology

Anand Mahadevan⁶  Alexander Muacevic⁸  David Perry⁷  Frank Kimsey²  John Pablo⁴  Sanjeev Sharma³  Clinton Medbery⁵  Joanne N. Davis¹ 

[1]The Radiosurgery Society®, 1350 Dell, Suite 105, Campbell 95008, CA, USA

[2]Department of Radiation Oncology, Erlanger Health System, Chattanooga, TN, USA

[3]Department of Radiation Oncology, St. Mary’s Medical Center, Huntington, WV, USA

[4]Department of Radiation Oncology, St. Joseph/Candler Hospital, Savannah, GA, USA

[5]Department of Radiation Oncology, St. Anthony Hospital, Oklahoma City, OK, USA

[6]Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

[7]Department of Radiation Oncology, Medstar Franklin Square Medical Center, Baltimore, MD, USA

[8]European CyberKnife Center Munich-Grosshadern and Munich University, Munich, Germany

关键词: RSSearch®;    Patient registry;    Lung metastasis;    Central lung tumors;    Lung cancer;    Stereotactic body radiotherapy;   

Others  :  1228532
DOI  :  10.1186/s13014-015-0417-5

 received in 2014-12-08, accepted in 2015-05-02,  发布年份 2015

【 摘 要 】

Background

The purpose of this study was to evaluate treatment patterns and outcomes of stereotactic body radiotherapy (SBRT) for centrally located primary non-small cell lung cancer (NSCLC) or lung metastases from the RSSearch^® Patient Registry, an international, multi-center patient registry dedicated to radiosurgery and SBRT.

Methods

Eligible patients included those with centrally located lung tumors clinically staged T1-T2 N0, M0, biopsy-confirmed NSCLC or lung metastases treated with SBRT between November 2004 and January 2014. Descriptive analysis was used to report patient demographics and treatment patterns. Overall survival (OS) and local control (LC) were determined using Kaplan-Meier method. Toxicity was reported using the Common Terminology Criteria for Adverse Events version 3.0.

Results

In total, 111 patients with 114 centrally located lung tumors (48 T1-T2,N0,M0 NSCLC and 66 lung metastases) were treated with SBRT at 19 academic and community-based radiotherapy centers in the US and Germany. Median follow-up was 17 months (range, 1–72). Median age was 74 years for primary NSCLC patients and 65 years for lung metastases patients (p < 0.001). SBRT dose varied from 16 – 60 Gy (median 48 Gy) delivered in 1–5 fractions (median 4 fractions). Median dose to centrally located primary NSCLC was 48 Gy compared to 37.5 Gy for lung metastases (p = 0.0001) and median BED₁₀ was 105.6 Gy for primary NSCLC and 93.6 Gy for lung metastases (p = 0.0005). Two-year OS for T1N0M0 and T2N0M0 NSCLC was 79 and 32.1 %, respectively (p = 0.009) and 2-year OS for lung metastases was 49.6 %. Two-year LC was 76.4 and 69.8 % for primary NSCLC and lung metastases, respectively. Toxicity was low with no Grade 3 or higher acute or late toxicities.

Conclusion

Overall, patients with centrally located primary NSCLC were older and received higher doses of SBRT than those with lung metastases. Despite these differences, LC and OS was favorable for patients with central lung tumors treated with SBRT. Reported toxicity was low, although low grade toxicities were observed in patients where dose tolerances approached or exceeded published guidelines. Prospective studies are needed to further define the optimal SBRT dose for this cohort of patients.

Trial registration

Clinicaltrials.gov Identifier: NCT01885299 webcite

【 授权许可】

   
2015 Davis et al.; licensee BioMed Central.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Crabtree TD, Denlinger CE, Meyers BF, El Naqa I, Zoole J, Krupnick AS et al.. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2010; 140:377-86.
• [2]Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J et al.. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010; 303:1070-6.
• [3]Verstegen NE, Oosterhuis JW, Palma DA, Rodrigues G, Lagerwaard FJ, van der Elst A et al.. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Ann Oncol. 2013; 24:1543-8.
• [4]Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K et al.. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011; 81:1352-8.
• [5]Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S et al.. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol. 2010; 28:928-35.
• [6]Norihisa Y, Nagata Y, Takayama K, Matsuo Y, Sakamoto T, Sakamoto M et al.. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys. 2008; 72:398-403.
• [7]Okunieff P, Petersen AL, Philip A, Milano MT, Katz AW, Boros L et al.. Stereotactic Body Radiation Therapy (SBRT) for lung metastases. Acta Oncologica (Stockholm, Sweden). 2006; 45:808-17.
• [8]Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA et al.. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009; 27:1579-84.
• [9]Song SY, Choi W, Shin SS, Lee SW, Ahn SD, Kim JH et al.. Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer (Amsterdam, Netherlands). 2009; 66:89-93.
• [10]Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J et al.. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006; 24:4833-9.
• [11]Chang JY, Li QQ, Xu QY, Allen PK, Rebueno N, Gomez DR et al.. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “no fly zone”. Int J Radiat Oncol Biol Phys. 2014; 88:1120-8.
• [12]Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol. 2011; 6:2036-43.
• [13]Milano MT, Chen Y, Katz AW, Philip A, Schell MC, Okunieff P. Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy. Radiother Oncol. 2009; 91:301-6.
• [14]Nuyttens JJ, van Van der Voort ZNC, Praag J, Aluwini S, van Klaveren RJ, Verhoef C et al.. Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors. Radiother Oncol. 2012; 102:383-7.
• [15]Osti MF, Carnevale A, Valeriani M, De Sanctis V, Minniti G, Cortesi E et al.. Clinical outcomes of single dose stereotactic radiotherapy for lung metastases. Clin Lung Cancer. 2013; 14:699-703.
• [16]Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Stereotactic body radiotherapy for central lung tumors. J Thorac Oncol. 2012; 7:1394-9.
• [17]Schanne DH, Nestle U, Allgauer M, Andratschke N, Appold S, Dieckmann U, et al. Stereotactic body radiotherapy for centrally located stage I NSCLC: A multicenter analysis. Strahlenther Onkol. 2015;191:125–32.
• [18]Unger K, Ju A, Oermann E, Suy S, Yu X, Vahdat S et al.. CyberKnife for hilar lung tumors: report of clinical response and toxicity. J Hematol Oncol. 2010; 3:39. BioMed Central Full Text
• [19]Bahig H, Filion E, Vu T, Roberge D, Lambert L, Bouchard M, et al. Excellent cancer outcomes following patient-adapted robotic lung SBRT but a case for caution in idiopathic pulmonary fibrosis. Technol Cancer Res Treat. 2014; [Epub ahead of print].
• [20]Daly ME, Perks JR, Chen AM. Patterns-of-care for thoracic stereotactic body radiotherapy among practicing radiation oncologists in the United States. J Thorac Oncol. 2013; 8:202-7.
• [21]Davis JN, Medbery Iii C, Sharma S, Danish A, Mahadevan A. The RSSearchTM Registry: patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy. Radiat Oncol. 2013; 8:275. BioMed Central Full Text
• [22]Grills IS, Hope AJ, Guckenberger M, Kestin LL, Werner-Wasik M, Yan D et al.. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol. 2012; 7:1382-93.
• [23]Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K et al.. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007; 2:S94-100.
• [24]Nishimura S, Takeda A, Sanuki N, Ishikura S, Oku Y, Aoki Y et al.. Toxicities of organs at risk in the mediastinal and hilar regions following stereotactic body radiotherapy for centrally located lung tumors. J Thorac Oncol. 2014; 9:1370-6.
• [25]Onimaru R, Shirato H, Shimizu S, Kitamura K, Xu B, Fukumoto S et al.. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys. 2003; 56:126-35.
• [26]Bral S, Gevaert T, Linthout N, Versmessen H, Collen C, Engels B et al.. Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial. Int J Radiat Oncol Biol Phys. 2011; 80:1343-9.
• [27]Collins BT, Vahdat S, Erickson K, Collins SP, Suy S, Yu X et al.. Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancer. J Hematol Oncol. 2009; 2:1. BioMed Central Full Text
• [28]Hoogeman M, Prevost JB, Nuyttens J, Poll J, Levendag P, Heijmen B. Clinical accuracy of the respiratory tumor tracking system of the cyberknife: assessment by analysis of log files. Int J Radiat Oncol Biol Phys. 2009; 74:297-303.
• [29]Prevost JB, Voet P, Hoogeman M, Praag J, Levendag P, Nuyttens JJ. Four-dimensional stereotactic radiotherapy for early stage non-small cell lung cancer: a comparative planning study. Technol Cancer Res Treat. 2008; 7:27-33.
• [30]Chang JY, Balter PA, Dong L, Yang Q, Liao Z, Jeter M et al.. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008; 72:967-71.
• [31]Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA et al.. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009; 75:677-82.
• [32]Derycke S, Van Duyse B, De Gersem W, De Wagter C, De Neve W. Non-coplanar beam intensity modulation allows large dose escalation in stage III lung cancer. Radiother Oncol. 1997; 45:253-61.
• [33]Dong P, Lee P, Ruan D, Long T, Romeijn E, Low DA et al.. 4pi noncoplanar stereotactic body radiation therapy for centrally located or larger lung tumors. Int J Radiat Oncol Biol Phys. 2013; 86:407-13.
• [34]Rossi L, Breedveld S, Heijmen BJ, Voet PW, Lanconelli N, Aluwini S. On the beam direction search space in computerized non-coplanar beam angle optimization for IMRT-prostate SBRT. Phys Med Biol. 2012; 57:5441-58.